Last updated: 11/07/2018 10:21:00

Validation of the new COPD assessment test (CAT) translated into Thai in patients with Chronic Obstructive Pulmonary Disease (COPD)CAT, COPD

GSK study ID
116316
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Validation of the new COPD assessment test (CAT) translated into Thai in patients with Chronic Obstructive Pulmonary Disease (COPD)
Trial description: This is a cross-sectional validation study, designed to evaluate the discriminative validity of the CAT translated in a local language in patients with COPD.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

• Correlation of the CAT with SGRQ

Timeframe: 5 months

Secondary outcomes:

• Correlation of the CAT with FEV1 values.

Timeframe: 5 months

• Correlation of the CAT with MRC dyspnea scale

Timeframe: 5 months

Interventions:
Not applicable
Enrollment:
98
Primary completion date:
Not applicable
Observational study model:
Other
Time perspective:
Prospective
Clinical publications:
Chaicharn Pothirat, Sumalee Kiatboonsri, Charoen Chuchottawon.Validation of the new COPD Assessment Test (CAT) translated into Thai in patients with Chronic Obstructive Pulmonary Disease (COPD).BMC Pulm Med.2014
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
Not applicable
Collaborators
Not applicable
Study date(s)
April 2012 to August 2012
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
40+ years
Accepts healthy volunteers
none
  • meet all criterias
  • Type of subject: Outpatients
  • meet any criteria
  • Asthma: Subjects with a current diagnosis of asthma. Subjects with a prior history of asthma are eligible if COPD is the current diagnosis.
Inclusion and exclusion criteria
Inclusion criteria:
  • meet all criterias
  • Type of subject: Outpatients
  • Informed consent: Subjects must give their signed and dated written informed consent to participate.
  • Gender: Male or Female
  • Age: 40 years of age or older at a clinic visit
  • COPD diagnosis: Subjects with an established diagnosis of COPD based on post-bronchodilator FEV1/FVC < 0.7 in the past 6 months or before.
  • Tobacco use: Smokers or ex-smokers with a smoking history of more than 10 pack years.
Exclusion criteria:
  • meet any criteria
  • Asthma: Subjects with a current diagnosis of asthma. Subjects with a prior history of asthma are eligible if COPD is the current diagnosis.
  • Lung diseases: Subjects with current active respiratory disorders other than COPD, e.g. lung cancer, tuberculosis or other significant chest x-rays findings are not explained by COPD (documented within 1 year).
  • Non-compliance: Unable to complete questionnaires

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2012-05-08

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website